Compare Walt Disney Co (DIS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Novartis AG — how do they compare? Walt Disney Co trades at $95.99 (market cap $166.48B), while Novartis AG trades at $150.44 (market cap $288.65B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| DIS | NVS | |
|---|---|---|
Market Cap | $166.48B | $288.65B |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $122.94 | $168.62 |
52-Week Low | $92.40 | $113.50 |
Enterprise Value | $208.16B | $328.67B |
Dividend Yield | 1.56% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $95.87, up 0.25% with a P/E of 15.36 and strong earnings beats in recent quarters. The company shows robust fundamentals with $94.43B revenue and $12.40B net income in 2025, though technical indicators signal bearish momentum. Recent news highlights advertising opportunities with major events and regulatory challenges with the FCC.
Outlook remains positive with analyst consensus at $125.60 target, representing 31% upside. Key opportunities include sports broadcasting rights and theme park recovery, while risks involve box office performance and regulatory pressures. The stock offers value with improving profitability and strong cash flow generation.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
